|
|
||||||||
Ann Thorac Surg 2005;79:772-775
© 2005 The Society of Thoracic Surgeons
a Heart Center, University of Leipzig, Leipzig, Germany
b Clinic for Cardiac Surgery and Cardiology, Leipzig, Germany
Accepted for publication August 13, 2004.
* Address reprint requests to Dr Walther, Universität Leipzig, Herzzentrum, Klinik für Herzchirurgie, Strümpellstr 39, 04289 Leipzig, Germany (E-mail: walt{at}medizin.uni-leipzig.de).
BACKGROUND: Our aim is to describe the clinical experience with stentless mitral valve (SMV) replacement with special focus on the functionality of the SMV.
METHODS: Fifty-two patients (68 ± 8.5 years old; 36 female) have been prospectively evaluated since August 1997. The chordally supported SMV (Quattro) was implanted for mitral stenosis (n = 26), severe incompetence (n = 17), or mixed lesion (n = 9). Preoperative New York Heart Association class was 3.1 ± 0.6. Twenty patients received additional intraoperative ablation therapy. Mean follow-up is 37.3 ± 18.7 months (range, 1 to 65).
RESULTS: Surgery was performed using conventional sternotomy (33) or anterolateral minithoracotomy (19). Atrial rhythm was reestablished in 17 of 20 patients. Six patients operated on early in this series required reoperation, 2 for paravalvular leakage, 2 for functional stenosis, 1 with pannus formation due to underlying rheumatoid disease, and 1 for papillary flap rupture after 5.1 years. Mortality was 1 perioperative (1.9%, nonvalve related) and 1 after reoperation due to multiorgan failure. During late follow-up (30 ± 7 months postoperatively) 5 patients died of noncardiac causes. Regular echocardiographic control revealed good SMV function (maximum transmitral blood flow velocity 1.7 ± 0.2 m/s; mean transmitral pressure gradient 3.9 ± 1.2 mm Hg) and well-preserved ejection fraction postoperatively as well as at most recent follow-up.
CONCLUSIONS: The clinical experience after 5.5 years of SMV implantation is promising. Preservation of annuloventricular continuity is advantageous. However, long-term durability remains to be proved.
This article has been cited by other articles:
![]() |
S. Kabbani, H. Jamil, F. Nabhani, A. Hamoud, K. Katan, N. Sabbagh, A. Koudsi, L. Kabbani, and G. Hamed Analysis of 92 mitral pulmonary autograft replacement (Ross II) operations. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 902 - 908.e7. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Magne, P. Mathieu, J. G. Dumesnil, D. Tanne, F. Dagenais, D. Doyle, and P. Pibarot Impact of Prosthesis-Patient Mismatch on Survival After Mitral Valve Replacement Circulation, March 20, 2007; 115(11): 1417 - 1425. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Keeling, T. S. Maxey, D. Sayad, N. Martini, E. Blazick, and K. E. Sommers A Novel Stentless Mitral Valve Surgical Innovation, March 1, 2007; 14(1): 9 - 11. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |